Trial Profile
Neoadjuvant Chemoradiotherapy (Gemcitabine/Cisplatin and Taxotere) With or Without Co-Administration of ZD 1839 (Iressa) for Stage IIIA (N2) and Selective Stage IIIB Non-Small Cell Lung Cancer: Phase I-II Study.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary) ; Cisplatin; Docetaxel; Gemcitabine
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 03 Oct 2005 New trial record.